Litholink Laboratory Reporting System<sup>™</sup>

## Patient Results Report

PATIENT **Patient, Sample**  DATE OF BIRTH 06/30/1994 PHYSICIAN **Physician, Sample** 

Sample Physician MD Sample Practice 2250 W. Campbell Park Dr. Chicago, IL 60612

### **Current Test Overview**

S000000	2	08/03/2005	08/04/2005	08/06/2005	
SAMPLE ID	(IN DAYS)	DATE	DATE	DATE	SAMPLE BARCODE
	TURNAROUND	COLLECTION	RECEIPT	COMPLETION	
	<b>RESULTS</b>	PATIENT	LAB	TEST	

Litholink's computer generated comments are based upon the patient's most recent laboratory results without taking into account concurrent use of medication or dietary therapy. They are intended solely as a guide for the treating physician. Litholink does not have a doctor-patient relationship with the individuals for whom tests are ordered, nor does it have access to a complete medical history, which is required for both a definitive diagnosis and treatment plan. Cys 24, Cys Capacity, Sulfate, and Citrate were developed and their performance characteristics determined by Litholink Corporation. It has not been cleared or approved by the US Food and Drug Administration.

Page 1 of 5



Laboratory Director CLIA# 14D0897314

Mitchell S. Laks, Ph.D. Litholink Corporation 2250 West Campbell Park Drive Chicago, Illinois 60612

800 338 4333 Telephone 312 243 3297 Facsimile www.litholink.com

Date Printed: 5/9/2006

PATIENT **Patient, Sample**  DATE OF BIRTH 06/30/1994

PHYSICIAN **Physician, Sample** 

### **Pediatric Chemistry Data**

Values larger, bolder and more towards red indicate increasing risk for kidney stone formation.

DATE	SAMPLE ID	SS CaOx	Ca 24 /Kg	0x 24 /1.73m <sup>2</sup>	Cit 24 /Cr 24	рН	UA 24 /1.73m²	P 24 /Kg	Mg 24 /Kg	HEIGHT WEIGHT
08/03/05	S147624	12.76	3.0	36.7	1028	6.115	0.40	15	1.6	154.9 43.5

ABBR.	ANALYTE	TREATMENT RECOMMENDATION
SS CaOx	Supersaturation CaOx	Reduce levels by raising urine volume and citrate, lowering urine oxalate and calcium. (J Urol 158:157, 1997)
Ca 24/Kg	24 hr calcium per Kg body weight	mg/kg; <3.7 both genders; if not associated with hypercalcemia consider thiazide diuretic. (Arch Dis Child 49:97, 1974)
0x 24/1.73 m <sup>2</sup>	24 hr oxalate / 1.73 m2	mg/1.73 m <sup>2</sup> /24 hr; high from diet excess, severe elevation consider genetic cause or bowel disease. (J Urol 158:157, 1997)
Cit 24/Cr 24	24 hr citrate / 24 hr creatinine	mg citrate/gr creat; male >130, female >300; if low consider potassium citrate. (J Pediatr 92:394, 1978)
рН	24 hr urine pH	Low pH can cause uric acid stones, treat with alkali; if>8 consider urea splitting infection. (J Urol 158:157, 1997)
UA 24/1.73 m <sup>2</sup>	24 hr uric acid / 1.73 m2	gram/1.73 m <sup>2</sup> /24 hr; <0.81 both genders; high from diet or inborn errors of purine metabolism. (J Pediatr 92:911, 1978)
P 24/Kg	24 hr phosphorous / Kg body weight	mg/kg/24 hr; low in poor nutrition or bowel disease, high from diet intake especially dairy . (J Urol 158:157, 1997)
Mg 24/Kg	24 hr magnesium / Kg body weight	mg/kg/24 hr; low in poor nutrition or bowel disease. (J Urol 158:157, 1997)
Height	Height in cm	Obtained from treating physician or patient.
Weight	Body Weight in Kg	Obtained from treating physician or patient.
Page 2 of	5	Date Printed: 5/9/2006

LitholinkStone Kidney Stone Prevention Program"

Laboratory Director CLIA# 14D0897314

Mitchell S. Laks, Ph.D. Litholink Corporation 2250 West Campbell Park Drive Chicago, Illinois 60612

800 338 4333 Telephone 312 243 3297 Facsimile www.litholink.com

PATIENT **Patient, Sample**  DATE OF BIRTH 06/30/1994 PHYSICIAN **Physician, Sample** 

### **Pediatric Normal Ranges**

Chemistry	AGE	MALE MEAN	MALE SD	FEMALE MEAN	FEMALE SD
SS CaOx	0 - 3.9	6.5	8.2	4.4	3.9
	4 - 6.9	6.2	4.7	4.1	3.2
	7 - 9.9	8.8	13.1	5.5	4.3
	10 - 12.9	7.0	6.2	5.5	4.6
	13 - 16	5.3	4.6	3.3	3.9
Ca 24/Kg	1 - 16	2.4	0.7	2.4	0.7
0x24/1.73m2	0 - 3.9	35.4	22.7	30.4	17.7
	4 - 6.9	35.3	25.9	29.0	18.3
	7 - 9.9	28.2	11.1	30.4	21.5
	10 - 12.9	28.9	14.7	27.6	38.3
	13 - 16	30.1	24.3	28.2	21.6
Cit 24/Cr 24	1 - 16	457	164	681	191
рH	0 - 3.9	6.70	0.8	6.90	0.79
	4 - 6.9	6.45	0.67	6.50	0.4
	7 - 9.9	6.27	0.61	6.34	0.61
	10 - 12.9	6.38	0.54	6.38	0.88
	13 - 16	6.41	0.59	6.37	0.64
Ua24/1.73m2	1 - 16	0.52	0.15	0.52	0.15
P 24/Kg	0 - 3.9	24.4	7.5	13.8	7.0
	4 - 6.9	17	10.5	14.8	5.9
	7 - 9.9	16.4	7.4	14.3	7.2
	10 - 12.9	15.5	7.0	11.1	5.2
	13 - 16	13.3	8.1	13.1	6.9
Mg 24/Kg	0 - 3.9	2.1	1.1	1.7	1.1
	4 - 6.9	2.1	1.3	2.0	1.3
	7 - 9.9	2.1	1.2	2.0	1.3
	10 - 12.9	1.7	0.9	1.2	0.9
	13 - 16	1.3	1.5	1.2	0.6

Page 3 of 5



Mitchell S. Laks, Ph.D. Litholink Corporation Laboratory Director CLIA# 14D0897314

2250 West Campbell Park Drive Chicago, Illinois 60612

Date Printed: 5/9/2006

800 338 4333 Telephone 312 243 3297 Facsimile www.litholink.com

PATIENT	DATE OF BIRTH	PHYSICIAN
Patient, Sample	06/30/1994	Physician, Sample

Values larger, bolder and more towards red indicate increasing risk for kidney stone formation. See reverse for further details.

#### Stone Risk Factors / Cystine Screening: Negative (08/05/2005)

DATE	SAMPLE ID	Vol 24	SS CaOx	Ca 24	0x 24	Cit 24	SS CaP	рН	SS UA	UA 24
08/03/05	S000000	0.78	12.76	131	29	668	2.20	6.115	0.65	0.320
NORM	AL RANGE	0.5 - 4L	6 - 10	male <250 female <200	20 - 40	male >450 female >550	0.5 - 2	5.8 - 6.2	0 - 1	male <0.800 female <0.750

### **Dietary Factors**

DATE	SAMPLE ID	Na 24	K 24	Mg 24	P 24	Nh4 24	CI 24	Sul 24	UUN 24	PCR
08/03/05	S000000	89	40	70	0.652	17	89	19	4.40	0.8
NORM	AL RANGE	50 - 150	20 - 100	30 - 120	0.6 - 1.2	15 - 60	70 - 250	20 - 80	6 - 17	0.8 - 1.4

### **Renal Function Normalized Values**

DATE	SAMPLE ID	WEIGHT	Cr 24	Cr 24/Kg	C Cr	Ca 24/Kg	Ca 24/Cr 24	
08/03/05	S000000	43.5	650	14.9		3.0	202	
NORM	AL RANGE			male 18-24 female 15-20	male >100 female >90	<4	<140	

Page 4 of 5



Mitchell S. Laks, Ph.D. Litholink Corporation Laboratory Director

2250 West Campbell Park Drive CLIA# 14D0897314 Chicago, Illinois 60612

Date Printed: 5/9/2006

800 338 4333 Telephone 312 243 3297 Facsimile www.litholink.com

PATIENT **Patient, Sample**  DATE OF BIRTH 06/30/1994 PHYSICIAN **Physician, Sample** 

#### **Clinical Report**

The clinical information shown below was obtained directly from your patient during our telephone interview, and, where possible, from medical records forwarded from your office.

Stone Morbitity	BEFORE TREATMENT	AFTER TREATMENT
First Stone Date:	06/08/2005	N/A
Total Stones:	2	0
ER Visits:	0	0
Hospital Visits:	0	0
Infections:	0	0
Cystoscopies:	1	0
Lithotripsies:	0	0
Operations:	0	0
Treatment Began:	N/A	11/02/2005

Surgical History		EVENT DATE
Dietary History	START	STOP
Medication History		
DRUG (DOSE/DAY)	START	STOP
<b>Related Diseases</b>		DIAGNOSED

#### **Family History**

No
No
1
0
0
0

#### **Contributing Factors**

Hot or dry environment:	No
Limited access to restroom:	No
Long term immobilization:	
Long term steroid therapy:	
Kidney removed:	

< = Before Treatment



#### Page 5 of 5



Mitchell S. Laks, Ph.D. Litholink Corporation Laboratory Director CLIA# 14D0897314

2250 West Campbell Park Drive Chicago, Illinois 60612

800 338 4333 Telephone 312 243 3297 Facsimile www.litholink.com

Date Printed: 5/9/2006